Sihuan Pharma Acquires TCM Cardiovascular Drug Maker for $120 Million

Sihuan Pharmaceutical paid 775 million RMB ($120 million) to acquire two China drug companies, Vinise Pharma and Hainan Litzman Pharma. The transaction adds to Sihuan’s portfolio of treatments for cardio-cerebral vascular diseases by taking the company into TCM preparations – Vinise Pharma’s specialty – for the first time. Vinise also has expertise in large-volume injections, another new area for Sihuan. More details.... Stock Symbol: (HK: 0460)     Share this with colleagues: